Spleen News and Research

RSS

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

Discovery provides hope for patients with pancreatic cancer

This week researchers in the Oregon Health & Science University (OHSU) Oregon Stem Cell Center and the OHSU Digestive Health Center are shining a new ray of hope on patients with pancreatic cancer. They've developed new reagents, or antibodies, that can recognize this often lethal disease. This important discovery may one day lead to earlier detection and treatment.

22 May 2008

Dendrimers improve imaging with magnetic nanoparticles

Dendrimers are spherical polymer nanoparticles that have shown promise as targeted anticancer drug delivery vehicles. Iron oxide nanoparticles have already demonstrated the ability to image tumors and metastatic lesions.

20 May 2008

Skin flaps deliver cancer-fighting therapy

Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

8 May 2008

New mucosal vaccine against anthrax effective in early tests

Early studies show that a new mucosal vaccine against anthrax has the potential to provide military personnel with more effective and efficient protection against a "popular" bioweapon, according to a study published in the journal Clinical and Vaccine Immunology (CVI).

13 Apr 2008

Proteolix's Carfilzomib granted orphan drug designation

Proteolix, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to carfilzomib, a selective blocker of proteasome activity for the treatment of multiple myeloma.

3 Apr 2008

Immune system needs food to function properly

Researchers studying deer mice have discovered evidence to support what mothers everywhere have long suspected: the immune system needs food to function properly.

2 Apr 2008

Groundbreaking surgery removes all abdominal organs to get at cancer

In groundbreaking surgery a patient has had all of the organs in the abdomen temporarily removed so surgeons could operate on a cancerous tumour.

25 Mar 2008

Aerosol vaccine provides low-cost, needle-free TB treatment

A novel aerosol version of the most common tuberculosis (TB) vaccine, administered directly to the lungs as an oral mist, offers significantly better protection against the disease in experimental animals than a comparable dose of the traditional injected vaccine, researchers report this week in the Proceedings of the National Academy of Sciences.

13 Mar 2008

New nanotube findings give boost to potential biomedical applications

Carbon nanotubes have shown real promise as highly accurate vehicles for delivering antitumor agents into malignant cells, but a dearth of data about what happens to the tubes after they discharge their medical payloads has been a major stumbling block to progress.

3 Mar 2008

Nanotechnology advances brain cancer detection and therapy

Brain cancer is one of the most aggressive and lethal of malignancies, made even more difficult to treat by the fact that most anticancer drugs have a hard time even getting to the tumors.

3 Mar 2008

Clinical trial shows reduction in mortality for children with severe Langerhans cell histiocytosis

A new international study finds that introducing an increased intensity of chemotherapy in children with severe Langerhans cell histiocytosis (LCH) can reduce the mortality rate for this disorder by as much as 20 percent when the patient demonstrates a rapid response to such treatment.

3 Mar 2008